Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects

Journal of Immunology

Volumn 176, Issue 1, 2006, Pages 309-318

  Buhtoiarov, Ilia N ^a   Lum, Hillary D ^a   Berke, Gideon ^c   Sondel, Paul M ^a,b   Rakhmilevich, Alexander L ^a,b  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIBODY; CD40 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; INTERLEUKIN 12; MONOCLONAL ANTIBODY; NITRIC OXIDE; SILICON DIOXIDE; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; IMMUNOTHERAPY; MACROPHAGE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SCID MOUSE; T LYMPHOCYTE;

EID: 29644431786     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.1.309     Document Type: Article

References (60)

1. Langrish, C. L., B. S. McKenzie, N. J. Wilson, R. de Waal Malefyt, R. A. Kastelein, and D. J. Cua. 2004. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol. Rev. 202: 96-105.
2. Abe, K., M. Harada, K. Tamada, O. Ito, T. Li, and K. Nomoto. 1998. Early-appearing tumor-infiltrating natural killer cells play an important role in the nitric oxide production of tumor-associated macrophages through their Interferon production. Cancer Immunol. Immunother. 45: 225-233.
3. Tsung, K., J. P. Dolan, Y. L. Tsung, and J. A. Norton. 2002. Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection. Cancer Res. 62: 5069-5075.
4. Buhtoiarov, I. N., H. Lum, G. Berke, D. M. Paulnock, P. M. Sondel, and A. L. Rakhmilevich. 2005. CD40 ligation activates murine macrophages via an IFN-γ-dependent mechanism resulting in tumor cell destruction in vitro. J. Immunol. 174: 6013-6022.
5. Schroder, K., P. J. Hertzog, T. Ravasi, and D. A. Hume. 2004. Interferon-γ: an overview of signals, mechanisms and functions. J. Leukocyte Biol. 75: 163-189.
6. Ahmad-Nejad, P., H. Hacker, M. Rutz, S. Bauer, R. M. Vabulas, and H. Wagner. 2002. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur. J. Immunol. 32: 1958-1968.
7. Held, T. K., X. Weihua, L. Yuan, D. V. Kalvakolanu, and A. S. Cross. 1999. γ interferon augments macrophage activation by lipopolysaccharide by two distinct mechanisms, at the signal transduction level and via an autocrine mechanism involving lumor necrosis factor α and interleukin-1. Infect. Immun. 67: 206-212.
8. Taylor, P. R., L. Martinez-Pomares, M. Stacey, H. H. Lin, G. D. Brown, and S. Gordon. 2005. Macrophage receptors and immune recognition. Annu. Rev. Immunol. 23: 901-944.
9. Schmid, B., M. J. Finnen, J. L. Harwood, and S. K. Jackson. 2003. Acylation of lysophosphatidylcholine plays a key role in the response of monocytes to lipopolysaccharide. Eur. J. Biochem. 270: 2782-2789.
10. Coelho, P. S., A. Klein, A. Talvani, S. F. Coutinho, O. Takeuchi, S. Akira, J. S. Suva, H. Canizzaro, R. T. Gazzinelli, and M. M. Teixeira. 2002. Glycosylphosphatidylinositol-anchored mucin-like glycoproteins isolated from Trypanosoma cruzi trypomastigotes induce in vivo leukocyte recruitment dependent on MCP-1 production by IFN-γ-primed-macrophages. J. Leukocyte Biol. 71: 837-844.
11. Ma, J., T. Chen, J. Mandelin, A. Ceponis, N. E. Miller, M. Hukkanen, G. F. Ma, and Y. T. Konttinen. 2003. Regulation of macrophage activation. Cell. Mol. Life Sci. 60: 2334-2346.
12. Werling, D., J. C. Hope, C. J. Howard, and T. W. Jungi. 2004. Differential production of cytokines, reactive oxygen and nitrogen by bovine macrophages and dendritic cells stimulated with Toll-like receptor agonists. Immunology 111: 41-52.
13. Schwamberger, G., P. Hammerl, E. Ferber, M. Freudenberg, and C. Galanos. 2003. TNF revisited: TNF-independent antitumor activity in sera of mice sensitized with Propionibacterium acnes and challenged with lipopolysaccharide. J. Leukocyte Biol. 74: 1056-1063.
14. Adams, D. O., and T. A. Hamilton. 1984. The cell biology of macrophage activation. Annu. Rev. Immunol. 2: 283-318.
15. Agostini, C., R. Zambello, L. Trentin, A. Cerutti, C. Enthammer, M. Facco, A. Milani, R. Sancetta, S. Garbisa, and G. Semenzato. 1995. Expression of TNF receptors by T cells and membrane TNF-α by alveolar macrophages suggests a role for TNF-α in the regulation of the local immune responses in the lung of HIV-1-infected patients. J. Immunol. 154: 2928-2938.
16. Herbeuval, J. P., C. Lambert, O. Sabido, M. Cottier, P. Fournel, M. Dy, and C. Genin. 2003. Macrophages from cancer patients: analysis of TRAIL, TRAIL receptors, and colon tumor cell apoptosis. J. Natl. Cancer Inst. 95: 611-621.
17. Halaas, O, R. Vik, A. Ashkenazi, and T. Espevik. 2000. Lipopolysaccharide induces expression of APO2 ligand/TRAIL in human monocytes and macrophages. Scand. J. Immunol. 51: 244-250.
18. Chong, Y. C., G. H. Heppner, L. A. Paul, and A. M. Fulton. 1989. Macrophage-mediated induction of DNA strand breaks in target tumor cells. Cancer Res. 49: 6652-6657.
19. Guiducci, C., A. P. Vicari, S. Sangaletti, G. Trinchieri, and M. P. Colombo. 2005. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 65: 3437-3446.
20. Masztalerz, A., N. Van Rooijen, W. Den Otter, and L. A. Everse. 2003. Mechanisms of macrophage cytotoxicity in IL-2 and IL-12 mediated tumour regression. Cancer Immunol. Immunother. 52: 235-242.
21. Boyle, J. J. 2004. Human macrophages kill human mesangial cells by Fas-L-induced apoptosis when triggered by antibody via CD16. Clin. Exp. Immunol. 137: 529-537.
22. Fishman, M. 1991. Cytolytic activities of activated macrophages versus paraformaldehyde-fixed macrophages; soluble versus membrane-associated TNF. Cell. Immunol. 137: 164-174.
23. Chen, G. G., Y. S. Chu, E. C. Chak, B. C. Leung, and W. S. Poon. 2002. Induction of apoptosis in glioma cells by molecules released from activated macrophages. J. Neurooncol. 57: 179-186.
24. Leu, R. W., N. R. Leu, B. J. Shannon, and D. J. Fast. 1991. IFN-γ differentially modulates the susceptibility of L1210 and P815 tumor targets for macrophage-mediated cytotoxicity. Role of macrophage-target interaction coupled to nitric oxide generation, but independent of tumor necrosis factor production. J. Immunol. 147: 1816-1822.
25. Havell, E. A., W. Fiers, and R. J. North. 1988. The antitumor function of tumor necrosis factor (TNF). I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity. J. Exp. Med. 167: 1067-1085.
26. + T cells. Immunity 22: 371-383.
27. Turner, J. G., A. L. Rakhmilevich, L. Burdelya, Z. Neal, M. Imboden, P. M. Sondel, and H. Yu. 2001. Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells. J. Immunol. 166: 89-94.
28. French, R. R., H. T. C. Chan, A. L. Tutt, and M. J. Glennie. 1999. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat. Med. 5: 548-553.
29. Ashkar, A. A., and K. L. Rosenthal. 2002. Toll-like receptor 9, CpG DNA and innate immunity. Curr. Mol. Med. 2: 545-556.
30. Utaisincharoen, P., N. Anuntagool, P. Chaisuriya, S. Pichyangkul, and S. Sirisinha. 2002. CpG-ODN activates NO and iNOS production in mouse macrophage cell line (RAW 264.7). Clin. Exp. Immunol. 128: 467-473.
31. Latz, E., A. Schoenemeyer, A. Visintin, K. A. Fitzgerald, B. G. Monks, C. F. Knetter, E. Lien, N. J. Nilsen, T. Espevik, and D. T. Golenbock. 2004. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat. Immunol. 5: 190-198.
32. Yeo, S. J., D. Gravis, J. G. Yoon, and A. K. Yi. 2003. Myeloid differentiation factor 88-dependent transcriptional regulation of cyclooxygenase-2 expression by CpG DNA: role of NF-κB and p38. J. Biol. Chem. 278: 22563-22573.
33. Gao, J. J., V. Diesl, T. Wittmann, D. C. Morrison, J. L. Ryan, S. N. Vogel, and M. T. Follettie. 2002. Regulation of gene expression in mouse macrophages stimulated with bacterial CpG-DNA and lipopolysaccharide. J. Leukocyte Biol. 72: 1234-1245.
34. Gao, J. J., V. Diesl, T. Wittmann, D. C. Morrison, J. L. Ryan, S. N. Vogel, and M. T. Follettie. 2003. Bacterial LPS and CpG DNA differentially induce gene expression profiles in mouse macrophages. J. Endotoxin Res. 9: 237-243.
35. Okano, F., M. Merad, K. Furumoto, and E. G. Engleman. 2005. In vivo manipulation of dendritic cells overcomes tolerance to unmodified tumor-associated self-antigens and induces potent antitumor immunity. J. Immunol. 174: 2645-2652.
36. Suzuki, Y., D. Wakita, K. Chamoto, Y. Narita, T. Tsuji, T. Takeshima, H. Gyobu, Y. Kawarada, S. Kondo, S. Akira, et al. 2004. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity. Cancer Res. 64: 8754-8760.
37. Rakhmilevich, A. L. 1995. Neutrophils are essential for resolution of primary and secondary infection with Listeria monocytogenes. J. Leuk. Biol. 57: 827-831.
38. Kirikae, T., H. Tamura, M. Hashizume, F. Kirikae, Y. Uemura, S. Tanaka, T. Yokochi, and M. Nakano. 1997. Endotoxin contamination in fetal bovine serum and its influence on tumor necrosis factor production by macrophage-like cells J774.1 cultured in the presence of the serum. Int. J. Immunopharmacol. 19: 255-262.
39. Scott, M. J., J. J. Hoth, M. K. Stagner, S. A. Gardner, J. C. Peyton, and W. G. Cheadle. 2004. CD40-CD154 interactions between macrophages and natural killer cells during sepsis are critical for macrophage activation and are not interferon γ dependent. Clin. Exp. Immunol. 137: 469-477.
40. Shibata, S., T. Asano, A. Ogura, N. Hashimoto, J. Hayakawa, K. Uetsuka, H. Nakayama, and K. Doi. 1997. SCID-bg mice as xenograft recipients. Lab. Anim. 31: 163-168.
41. Lecoeur, H., E. Ledru, M. C. Prevost, and M. L. Gougeon. 1997. Strategies for phenotyping apoptotic peripheral human lymphocytes comparing ISNT, annexin-V and 7-AAD cytofluorometric staining methods. J. Immunol. Methods 209: 111-123.
42. Hayashi, F., T. K. Means, and A. D. Luster. 2003. Toll-like receptors stimulate human neutrophil function. Blood 102: 2660-2669.
43. Zagozdzon, R., J. Golab, T. Stoklosa, A. Giermasz, D. Nowicka, W. Feleszko, W. Lasek, and M. Jakobisiak. 1998. Effective chemo-immunotherapy of L1210 leukemia in vivo using interleukin-12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatin. Int. J. Cancer 77: 720-727.
44. Auricchio, G., S. K. Garg, A. Martino, E. Volpe, A. Ciaramella, P. De Vito, P. M. Baldini, V. Colizzi, and M. Fraziano. 2003. Role of macrophage phospholipase D in natural and CpG-induced antimycobacterial activity. Cell. Microbiol. 5: 913-920.
45. Bourke, E., D. Bosisio, J. Golay, N. Polentarutti, and A. Mantovani. 2003. The Toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLRlO in normal and transformed cells. Blood 102: 956-963.
46. Wagner, M., H. Poeck, B. Jahrsdoerfer, S. Rothenfusser, D. Prell, B. Bohle, E. Tuma, T. Giese, J. W. Ellwart, S. Endres, and G. Hartmann. 2004. IL-12p70-dependent Th1 induction by human B cells requires combined activation with CD40 ligand and CpG DNA. J. Immunol. 172: 954-963.
47. Krug, A., A. Towarowski, S. Britsch, S. Rothenfusser, V. Hornung, R. Bals, T. Giese, H. Engelmann, S. Endres, A. M. Krieg, and G. Hartmann. 2001. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur. J. Immunol. 31: 3026-3037.
48. Gao, J. J., Q. Xue, C. J. Papasian, and D. C. Morrison. 2001. Bacterial DNA and lipopolysaccharide induce synergistic production of TNF-α through a post-transcriptional mechanism. J. Immunol. 166: 6855-6860.
49. Dalpke, A. H., S. Eckerle, M. Frey, and K. Heeg. 2003. Triggering of Toll-like receptors modulates IFN-γ signaling: involvement of serine 727 STAT1 phosphorylation and suppressors of cytokine signaling. Eur. J. Immunol. 33: 1776-1787.
50. Suzuki, K., T. Suda, T. Naito, K. Ide, K. Chida, and H. Nakamura. 2005. Impaired Toll-like receptor 9 expression in alveolar macrophages with no sensitivity to CpG DNA. Am. J. Respir. Crit. Care. Med. 171: 707-713.
51. Ropert, C., M. Closel, A. C. Chaves, and R. T. Gazzinelli. 2003. Inhibition of a p38/stress-activated protein kinase-2-dependent phosphatase restores function of IL-1 receptor-associate kinase-1 and reverses Toll-like receptor 2- and 4-dependent tolerance of macrophages. J. Immunol. 171: 1456-1465.
52. Iwasaki, A., and R. Medzhitov. 2004. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5: 987-995.
53. Bennett, S. R., F. R. Carbone, F. Karamalis, R. A. Flavell, J. F. A. Miller, and W. R. Heath. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393: 478-480.
54. Farmer, H., N. McCabe, C. J. Lord, A. N. Tutt, D. A. Johnson, T. B. Richardson, M. Santarosa, K. J. Dillon, I. Hickson, C. Knights, et al. 2005. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917-921.
55. Lonsdorf, A. S., H. Kuekrek, B. V. Stern, B. O. Boehm, P. V. Lehmann, and M. Tary-Lehmann. 2003. Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity. J. Immunol. 171: 3941-3946.
56. Chen, W., Y. Yu, C. Shao, M. Zhang, W. Wang, L. Zhang, and X. Cao. 2001. Enhancement of antigen-presenting ability of B lymphoma cells by immunostimulatory CpG-oligonucleotides and anti-CD40 antibody. Immunol. Lett. 77: 17-23.
57. Ballas, Z. K., A. M. Krieg, T. Warren, W. Rasmussen, H. L. Davis, M. Waldschmidt, and G. J. Weiner. 2001. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J. Immunol. 167: 4878-4886.
58. Auf, G., A. F. Carpentier, L. Chen, C. Le Clanche, and J. Y. Delattre. 2001. Implication of macrophages in tumor rejection induced by CpG-oligodeoxynucleotides without antigen. Clin. Cancer Res. 7: 3540-3543.
59. van Ojik, H. H., L. Bevaart, C. E. Dahle, A. Bakker, M. J. Jansen, M. J. van Vugt, J. G. van de Winkel, and G. J. Weiner. 2003. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. Cancer Res. 63: 5595-5600.
60. Solomayer, E. F., M. Feuerer, L. Bai, V. Umansky, P. Beckhove, G. C. Meyberg, G. Basiert, V. Schirrmacher, and I. J. Diel. 2003. Influence of adjuvant hormone therapy and chemotherapy on the immune system analyzed in the bone marrow of patients with breast cancer. Clin. Cancer Res. 9: 174-180.